Vivaldi Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Vivaldi Biosciences's estimated annual revenue is currently $2M per year.
- Vivaldi Biosciences's estimated revenue per employee is $155,000
Employee Data
- Vivaldi Biosciences has 13 Employees.
- Vivaldi Biosciences grew their employee count by 8% last year.
Vivaldi Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO, Director | Reveal Email/Phone |
2 | SVP, Manufacturing | Reveal Email/Phone |
3 | VP, Research & Development | Reveal Email/Phone |
4 | VP, Marketing & Communications | Reveal Email/Phone |
5 | CSO, Managing Director | Reveal Email/Phone |
6 | Associate Scientist | Reveal Email/Phone |
7 | Finance Administrator | Reveal Email/Phone |
Vivaldi Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 35 | 483% | $25M | N/A |
#2 | $2M | 13 | 18% | N/A | N/A |
#3 | $3.4M | 22 | 10% | N/A | N/A |
#4 | $68M | 439 | -3% | N/A | N/A |
#5 | $2M | 13 | 30% | N/A | N/A |
#6 | $4M | 26 | 8% | N/A | N/A |
#7 | $2.7M | 35 | -10% | $23.2M | N/A |
#8 | $5.3M | 34 | 70% | N/A | N/A |
#9 | $1.7M | 11 | -8% | N/A | N/A |
#10 | $3.1M | 20 | -17% | N/A | N/A |
What Is Vivaldi Biosciences?
Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technologies. Vivaldi's DeltaFLU universal influenza vaccine is in Phase 2 clinical development. Its Delta-19 universal influenza/Covid-19 vaccine will enter clinical trials in 2021. Delta NS1 is a versatile and robust technology platform for self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain. Delta NS1-based vaccines have the unique ability to rapidly induce interferon, generating protection against circulating viruses entering the nasal passages, and activating systemic antibody and cell-based protective immunity.
keywords:N/A
N/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Fort Collins
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.9M | 14 | 8% | $1.4M |
#2 | $0.7M | 14 | 17% | $9.5M |
#3 | $2.4M | 15 | -21% | N/A |
#4 | N/A | 15 | -6% | N/A |
#5 | $2.5M | 16 | -6% | N/A |